Biosimilar Sponsors Are Not Liable Under State Law For Declining Patent Dance
US Federal Circuit finds in Amgen v. Sandoz that the BPCIA preempts innovator companies from seeking penalties under state law against a biosimilar sponsor that does not engage in the 'patent dance.'
